Alzamend Neuro, Inc. (ALZN)
About Alzamend Neuro, Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$4.5M
- Total assets
- $4.6M
- Market cap
- $4.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $8.8M
- Operating income
- -$8.8M
- Net income
- $8.8M
- EPS (basic)
- $-2.63
- EPS (diluted)
- $-2.63
Balance sheet
- Total assets
- $2.1M
- Current assets
- $1.8M
- Total liabilities
- $1.3M
- Current liabilities
- $1.3M
- Shareholders’ equity
- $733.2K
Cash flow
- Operating cash flow
- -$8.1M
- Investing cash flow
- $3.2M
- Financing cash flow
- $4.8M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $4.2M
- EPS (diluted)
- $-2.63
- Shares outstanding
- 3.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 15, 2021
Alzamend Neuro, Inc. (ALZN) Stock Price
- Reported a net loss of $4.5M.
- Trading 62% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Alzamend Neuro, Inc..
Write a review
News about Alzamend Neuro, Inc.
News & sentiment via Polygon.io
Alzamend Neuro, Inc.: frequently asked questions
Is Alzamend Neuro, Inc. an American company?
Alzamend Neuro, Inc. is a US-based company headquartered in Atlanta, Georgia, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Alzamend Neuro, Inc. headquartered?
Alzamend Neuro, Inc. is headquartered in Atlanta, Georgia, United States.
Is Alzamend Neuro, Inc. publicly traded?
Yes — Alzamend Neuro, Inc. is a publicly traded company. Its stock trades under the ticker symbol ALZN on the NASDAQ.
What does Alzamend Neuro, Inc. do?
Alzamend Neuro, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
